From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).
about
Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.Strategies and challenges for the next generation of antibody-drug conjugates.Biosynthesis of the Enterotoxic Pyrrolobenzodiazepine Natural Product Tilivalline.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.A modular design for minor groove binding and recognition of mixed base pair sequences of DNA.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Novel pyrrolobenzodiazepine and pyrroloquinazoline scaffolds synthesized by a simple and highly selective Ugi/cyclization sequence.Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload.Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.Challenges and new frontiers in analytical characterization of antibody-drug conjugates.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.Novel pathway of 3-hydroxyanthranilic acid formation in limazepine biosynthesis reveals evolutionary relation between phenazines and pyrrolobenzodiazepines.An overview of recent advances in duplex DNA recognition by small molecules.Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulationDesign and 22-step synthesis of highly potent D-ring modified and linker-equipped analogs of spongistatin 1
P2860
Q38671475-FF0D9AA4-6848-4E16-9E9B-8CD9968D53B5Q39182945-D0F1F220-F9B0-4B67-8F13-1853D0F57FA8Q47424110-8E3C186F-C663-4AD6-BB23-1FA46D2ED693Q47661007-CBDFFCC8-442D-4C43-9099-FA24D525A24AQ47797367-116B53E0-D53E-4FDF-8FA4-02A0B20D0B07Q47816782-34ED8ED2-524C-43A0-ADE0-E19351F58579Q48113343-942D73B7-6D2B-4E1C-B1D5-A4F585524D3EQ48263612-F24DDE44-C041-40D4-AF8A-0BE9949BE061Q48677630-36707EDB-68D8-4062-B958-3A2D9C3475E1Q49949111-B25BF9E4-2A18-4A6B-B82D-A60827C4C60AQ50046714-4F3207FA-24BE-4654-A90E-25C1FBD7ADC8Q52401505-DF4471CC-E12D-4639-B2CA-F4CE86DBD040Q52593621-E7689824-8A8B-4FA0-AD3F-3E6C54CB0AF4Q55248458-D8C24FEC-13C8-48B5-BE3F-AC373C4B106EQ55476273-E092A49E-F7AC-41BD-A247-376014022ED3Q57139824-B46C39CD-DD3A-417E-9D94-1C0FF5F2F28CQ58568333-D2B30297-8FFD-49D0-8F97-794618AD87C0
P2860
From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
From Anthramycin to Pyrroloben ...... tibody-Drug Conjugates (ADCs).
@en
From Anthramycin to Pyrrolobenzodiazepine
@nl
type
label
From Anthramycin to Pyrroloben ...... tibody-Drug Conjugates (ADCs).
@en
From Anthramycin to Pyrrolobenzodiazepine
@nl
prefLabel
From Anthramycin to Pyrroloben ...... tibody-Drug Conjugates (ADCs).
@en
From Anthramycin to Pyrrolobenzodiazepine
@nl
P2860
P921
P356
P1476
From Anthramycin to Pyrroloben ...... ntibody-Drug Conjugates (ADCs)
@en
P2093
Julia Mantaj
Paul J M Jackson
P2860
P304
P356
10.1002/ANIE.201510610
P407
P5008
P577
2016-11-15T00:00:00Z
2017-01-09T00:00:00Z